VitaSpring Biomedical Co. Ltd.

Equities

VSBC

US92851B1026

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 19:03:41 11/08/2023 BST			5-day change	1st Jan Change
15 ^USD	+36.24%		-.--%	-.--%

2022	VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	CI
2022	VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	CI

VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2022

May 03, 2022 at 11:22 am

VitaSpring Biomedical Co. Ltd. reported earnings results for the full year ended January 31, 2022. For the full year, the company reported sales was USD 5.61 million compared to USD 0.2482 million a year ago. Net income was USD 1.26 million compared to net loss of USD 0.425382 million a year ago.

Latest news about VitaSpring Biomedical Co. Ltd.

VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2022	21/12/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2022	15/09/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2022	15/06/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2022	03/05/22	CI
VitaSpring Biomedical Co. Ltd. Auditor Raises 'Going Concern' Doubt	02/05/22	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended October 31, 2021	23/12/21	CI
QuantuMDx Group Limited announced that it has received ?15 million in funding from VitaSpring Biomedical Co. Ltd.	06/11/21	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2021	15/09/21	CI
Vitaspring Biomedical Co. Ltd. Announces Management Changes	11/08/21	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2021	14/06/21	CI
VitaSpring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2021	14/04/21	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Third Quarter Ended October 31, 2020	15/12/20	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Second Quarter Ended July 31, 2020	28/09/20	CI
VitaSpring Biomedical Co. Ltd. announced that it expects to receive $0.082342 million in funding	13/07/20	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the First Quarter Ended April 30, 2020	19/06/20	CI
Vitaspring Biomedical Co. Ltd. Reports Earnings Results for the Full Year Ended January 31, 2020	09/06/20	CI
SHEMN CORP will Change its Name to VitaSpring Biomedical Co. Ltd	21/04/20	CI
VitaSpring Biomedical Co. Ltd. will Change its Ticker to VSBC from SHNC	21/04/20	CI
Shemn Corp. Announces Management Changes	26/02/20	CI
Shemn Corp. Announces Management Changes	31/01/20	CI
Shemn Corp. Reports Earnings Results for the Third Quarter Ended October 31, 2019	12/12/19	CI
Shemn Corp. Reports Earnings Results for the Second Quarter Ended July 31, 2019	27/08/19	CI
Shemn Corp. Reports Earnings Results for the First Quarter Ended April 30, 2019	03/06/19	CI
Shemn Corp. Announces Executive Changes	17/04/19	CI
VitaSpring Biomedical Co. Ltd. has completed an IPO.	04/12/17	CI

Chart VitaSpring Biomedical Co. Ltd.

Duration

Period

More charts

Company Profile

Vitaspring Biomedical Co. Ltd. is focused on cell medical industry. The Company is engaged in the business of developing and marketing products that promote wellness and a healthy lifestyle. The Company invests in research and development of stem cell applications in regenerative medicine, establish advanced medical research centers and cell production centers and provides GTP standard stem cell preparations for the development of cellular drugs. The Company is focused on the fields of medicine, preventive health care, beauty, and anti-aging. It is also focused on developing X.MSC cytopharmaceuticals.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VITASPRING BIOMEDICAL CO. LTD.	-.--%	3.11B
VERTEX PHARMACEUTICALS INCORPORATED	+7.00%	113B
REGENERON PHARMACEUTICALS, INC.	+10.97%	106B
ARGENX SE	+0.61%	22.27B
BIONTECH SE	-12.34%	22.22B
GENMAB A/S	-5.20%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-6.18%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.88%	14.29B
SAREPTA THERAPEUTICS, INC.	+34.81%	12.52B

Bio Therapeutic Drugs